title: UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study.
abstract: Lamotrigine (LTG) is metabolized by UGT1A4 but UGT2B7 also contributes to its glucuronidation. The aim of this study was to determine whether UGT2B7_- 161C>T and UGT2B7_372A>G polymorphisms contribute to the intersubject variability in LTG concentration-to-dose ratio (LTG-CDR) in epileptic patients. Fifty-three white epileptic patients attending the Neuropediatric and Neurology Services at the Marqués de Valdecilla University Hospital, in whom LTG serum concentration was to be measured for pharmacokinetic monitoring, were selected according to predefined criteria for LTG-CDR evaluation. All patients had at least one steady-state LTG serum concentration obtained before the first dose in the morning. Patients were classified in 3 groups of comedication: (1) LTG in combination with metabolism-inducer anticonvulsants (n = 22), (2) LTG in combination with valproate (n = 13), and (3) LTG as monotherapy (n = 16) or in combination with valproate and inducers (n = 2). Genotypes were determined by Applied Biosystems Genotyping Assays with TaqMan probes. A significant association was found between LTG-CDR and UGT2B7_-161C>T polymorphism (P = 0.021) when patient age and concomitant antiepileptic drugs were taken into account. Comedication explained 70% of the LTG-CDR variability, patient age 24%, and UGT2B7_-161C>T 12%. In contrast, a significant association between LTG-CDR and this polymorphism was not found in the bivariate study when age and comedication groups were not considered. A significant association between UGT2B7_372A>G and LTG-CDR was not found in the bivariate or the multivariate studies. UGT2B7_-161C>T polymorphism is significantly associated with LTG-CDR when comedication with other antiepileptic drugs and patient age are taken into account in a multivariate analysis.
authors.affiliation: Service of Clinical Pharmacology, Marqués de Valdecilla University Hospital, University of Cantabria School of Medicine, Santander, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Blanca Sánchez
authors.forename: José L
authors.initials: JL
authors.lastname: Herranz
authors.forename: Carlos
authors.initials: C
authors.lastname: Leno
authors.forename: Rosa
authors.initials: R
authors.lastname: Arteaga
authors.forename: Agustín
authors.initials: A
authors.lastname: Oterino
authors.forename: Elsa M
authors.initials: EM
authors.lastname: Valdizán
authors.forename: José M
authors.initials: JM
authors.lastname: Nicolas
authors.forename: Javier
authors.initials: J
authors.lastname: Adín
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Shushtarian
authors.forename: Juan A
authors.initials: JA
authors.lastname: Armijo
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003596:Cytosine; D004305:Dose-Response Relationship, Drug; D005260:Female; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D013941:Thymine; D014227:Triazines / Q000008:administration & dosage* / Q000097:blood*; D055815:Young Adult
chemical_list: D014227:Triazines; D003596:Cytosine; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase; D013941:Thymine; D000077213:Lamotrigine